Compounds > verofylline
Page last updated: 2024-12-06

verofylline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID47845
CHEMBL ID2105599
SCHEMBL ID636856
MeSH IDM0095588

Synonyms (29)

Synonym
65029-11-0
1,8-dimethyl-3-(2-methyl-1-butyl)xanthine
3,7-dihydro-1,8-dimethyl-3-(2-methylbutyl)-1h-purine-2,6-dione
1h-purine-2,6-dione, 3,7-dihydro-1,8-dimethyl-3-(2-methylbutyl)-
verofylline (usan/inn)
D06291
66172-75-6
verofylline
ck-0383
1,8-dimethyl-3-(2-methylbutyl)-7h-purine-2,6-dione
CHEMBL2105599
verofylline [usan:inn]
(r,s)-1,2,3,6-tetrahydro-1,8-dimethyl-3-(2-(methylbutyl)-2,6-purindion
verofyllinum [inn-latin]
ck 0383
unii-1j8o1gt31u
verofilina
verofyllinum
(+-)-1,8-dimethyl-3-(2-methybutyl)xanthine
verofilina [inn-spanish]
1h-purine-2,6-dione, 3,7-dihydro-1,8-dimethyl-3-(2-methylbutyl)-, (+-)-
1j8o1gt31u ,
verofylline [inn]
verofylline [usan]
SCHEMBL636856
1,8-dimethyl-3-(2-methylbutyl)-3,7-dihydro-1h-purine-2,6-dione
Q27252489
DTXSID30867209
AKOS040754349

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Since Cl and Vss increased similarly, the half-life of verofylline in obese rats did not change."( Verofylline pharmacokinetics in dietary-induced obese rats: role of fat mass and protein binding in determining volume of distribution.
Jusko, WJ; Shum, L, 1991)		1.97

Dosage Studied

ExcerptRelevanceReference
" Peak expiratory flow, forced vital capacity, and its subdivisions were measured weekly 2, 4, and 6 hr after oral dosing with drug or placebo."( Verofylline, a methylxanthine bronchodilator, in asthma.
Booker, WM; Lucas, SG; Malveaux, FJ; Morris, EA; Pittman, J; Rachal, RE; Young, RC, 1984)		1.71
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (83.33)18.7374
1990's1 (16.67)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 42.34

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index42.34 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.29 (4.65)
Search Engine Demand Index91.05 (26.88)
Search Engine Supply Index3.00 (0.95)

This Compound (42.34)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (50.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other3 (50.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
theophylline
[no description available]		5.5263dimethylxanthineadenosine receptor antagonist;
anti-asthmatic drug;
anti-inflammatory agent;
bronchodilator agent;
drug metabolite;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
fungal metabolite;
human blood serum metabolite;
immunomodulator;
muscle relaxant;
vasodilator agent
indomethacin
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.		1.9610aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic
ConditionIndicatedRelationship StrengthStudiesTrials
Asthma, Bronchial
[description not available]		05.1843
Asthma
A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).		010.1843
Bronchospasm, Exercise-Induced
[description not available]		04.3122
Asthma, Exercise-Induced
Asthma attacks following a period of exercise. Usually the induced attack is short-lived and regresses spontaneously. The magnitude of postexertional airway obstruction is strongly influenced by the environment in which exercise is performed (i.e. inhalation of cold air during physical exertion markedly augments the severity of the airway obstruction; conversely, warm humid air blunts or abolishes it).		04.3122
Bronchospasm
[description not available]		01.9610
Bronchial Spasm
Spasmodic contraction of the smooth muscle of the bronchi.		01.9610
Obesity
A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).		01.9710